Hibiscus

Metadata

Approved Indications

Commission E (Germany)

• No Commission E monograph has been published for Hibiscus sabdariffa

ESCOP

• No ESCOP monograph has been published for Hibiscus sabdariffa

EMA/HMPC (European Medicines Agency)

• No EMA/HMPC monograph has been published for Hibiscus sabdariffa

Agreement/Disagreement Between Bodies

• No regulatory approval: None of the three major European herbal regulatory bodies have published a monograph for hibiscus
• Notable: Despite the absence of regulatory monographs, the clinical trial evidence base for blood pressure reduction is more substantial than for many herbs that do have approved monographs
• Context: Hibiscus is widely used as a traditional beverage rather than as a registered herbal medicine in Europe, which may partly explain the absence of formal regulatory assessment

Conditions Treated

Primary (Strong Evidence)

• Mild-to-moderate hypertension: Meta-analyses of multiple RCTs demonstrate statistically significant reductions in both systolic BP (~7 mmHg) and diastolic BP (~4 mmHg) compared to placebo

Secondary (Moderate Evidence)

• Dyslipidemia: Some RCTs show modest improvements in lipid profiles (total cholesterol, LDL), though results are inconsistent
• Metabolic syndrome markers: Preliminary evidence for improvements in fasting blood glucose and insulin sensitivity

Traditional/Historical (Limited Evidence)

• Urinary tract health (traditional diuretic use)
• Mild digestive complaints (the sour tea is used traditionally as a digestive aid)
• Kidney stone prevention (due to diuretic and citric acid content)
• Antioxidant supplementation (high anthocyanin content)
• Weight management (preliminary data only)

Mechanism of Action

Primary Mechanisms

ACE Inhibition (Renin-Angiotensin System):

• Anthocyanins delphinidin-3-sambubioside and cyanidin-3-sambubioside competitively inhibit angiotensin-converting enzyme (ACE) at the active site in vitro
• This prevents the conversion of angiotensin I to angiotensin II, reducing vasoconstriction and aldosterone secretion
• The mechanism is analogous to pharmaceutical ACE inhibitors, though weaker in potency

Endothelial Function and Nitric Oxide:

• Anthocyanins upregulate endothelial nitric oxide synthase (eNOS), promoting vasodilation
• Inhibition of inflammatory pathways in vascular endothelium contributes to improved vascular tone

Diuretic Effect:

• Hibiscus acid and other organic acids may contribute to a mild natriuretic (sodium-excreting) diuretic effect
• This may complement the vasodilatory mechanisms in lowering blood pressure

Secondary Mechanisms

Antioxidant Properties

• Hibiscus calyx is exceptionally rich in anthocyanins and polyphenols, contributing to high in vitro antioxidant capacity
• The anthocyanin profile is dominated by delphinidin and cyanidin glycosides, which are potent free radical scavengers
• Clinical relevance of the antioxidant activity for cardiovascular protection beyond blood pressure reduction is not firmly established

Clinical Evidence Summary

Volume of Evidence

• Moderate and growing. Multiple systematic reviews and meta-analyses have been published since 2015, incorporating data from numerous RCTs.

Key Studies

Blood Pressure Reduction (Primary Indication)

Comparison with Antihypertensive Drugs

• When compared with active controls (antihypertensive drugs), the difference in blood pressure reduction was not statistically significant, suggesting comparable but not superior efficacy to standard medications in mild hypertension

Subgroup Findings

• Blood pressure reductions are statistically significant in patients with hypertension alone, but not significant in patients with hypertension associated with metabolic syndrome
• Effects are most pronounced in individuals with elevated baseline blood pressure

Evidence Gaps

• No European regulatory assessment or approved monograph
• Limited long-term safety and efficacy data (most trials are 4-8 weeks)
• Insufficient data on dose-response relationships
• No standardized extract with consistent anthocyanin content across trials
• Limited data on hard cardiovascular endpoints (stroke, MI)

European vs US/Anglophone Consensus

Safety Profile

Contraindications

• Known hypersensitivity to Hibiscus sabdariffa or other Malvaceae plants
• Caution in patients with low blood pressure (hypotension) due to additive BP-lowering effects

Drug Interactions

• ACE inhibitors (captopril, enalapril, ramipril): Hibiscus has intrinsic ACE-inhibitory activity; coadministration with captopril has been shown in animal studies to alter captopril pharmacokinetics (reduced AUC and Cmax), potentially reducing drug efficacy. Concurrent use warrants monitoring
• Diuretics (hydrochlorothiazide): Animal studies suggest potential pharmacokinetic interaction; additive diuretic effects may increase risk of dehydration and electrolyte imbalance
• Antihypertensive medications (general): Additive blood pressure lowering; monitor for hypotension
• Chloroquine: One animal study reported reduced bioavailability of chloroquine when coadministered with hibiscus extract
• Acetaminophen (paracetamol): One study suggested altered pharmacokinetics; clinical significance is uncertain

Side Effects

• Generally well tolerated at typical doses
• Mild gastrointestinal disturbances (nausea, stomach discomfort, flatulence) are the most commonly reported side effects
• Diuretic effect may increase urination frequency
• Risk of dehydration with excessive consumption, particularly when combined with diuretic medications

Pregnancy/Lactation

• Pregnancy: Insufficient safety data; some traditional sources suggest emmenagogue properties. Avoid medicinal doses during pregnancy. Occasional dietary consumption of hibiscus tea is likely safe, but regular therapeutic use is not recommended
• Lactation: Insufficient data; not recommended in medicinal doses during breastfeeding
• Children: Insufficient data for children; not recommended in therapeutic doses for children under 12

Clinical Dosage

Standard Dosage Forms

Clinical Trial Doses

• McKay et al. 2010: 3 servings of 240 mL hibiscus tea daily (each brewed from 1.25 g dried calyx, totaling 3.75 g/day)
• Herrera-Arellano et al. 2007: Standardized calyx extract providing 9.6 mg total anthocyanins per dose
• Typical meta-analysis range: 1.5-10 g dried calyx daily as tea, or equivalent extract, for 2-8 weeks

Duration

• Clinical trials have typically lasted 2-8 weeks
• Blood pressure effects generally become apparent within 2-4 weeks
• Long-term use beyond 8 weeks has limited safety data

Sources

• Serban C, et al. Effect of sour tea (Hibiscus sabdariffa L.) on arterial hypertension: a systematic review and meta-analysis of randomized controlled trials. J Hypertens. 2015;33(6):1119-1127
• Najafpour Boushehri S, et al. Efficacy of Hibiscus sabdariffa on reducing blood pressure in patients with mild-to-moderate hypertension: a systematic review and meta-analysis. J Integr Med. 2020;18(5):414-420
• Fakhar E, et al. A systematic review and meta-analysis of the effects of Hibiscus sabdariffa on blood pressure and cardiometabolic markers. Nutr Rev. 2022;80(6):1723-1737
• McKay DL, et al. Hibiscus sabdariffa L. tea (tisane) lowers blood pressure in prehypertensive and mildly hypertensive adults. J Nutr. 2010;140(2):298-303
• Herrera-Arellano A, et al. Clinical effects produced by a standardized herbal medicinal product of Hibiscus sabdariffa on patients with hypertension. A randomized, double-blind, lisinopril-controlled clinical trial. Planta Med. 2007;73(1):6-12
• Mozaffari-Khosravi H, et al. Effects of sour tea (Hibiscus sabdariffa) on lipid profile and lipoproteins in patients with type II diabetes. J Altern Complement Med. 2009;15(8):899-903
• Ojulari OV, et al. Pharmacokinetic herb-drug interaction between Hibiscus sabdariffa calyces aqueous extract and captopril in rats. Evid Based Complement Alternat Med. 2020;2020:7384389
• Ndu OO, et al. Herb-drug interaction between the extract of Hibiscus sabdariffa L. and hydrochlorothiazide in experimental animals. J Pharmacol Toxicol. 2011;6(2):173-180

Connections

• Compare with Hawthorn as a cardiovascular herb with stronger European regulatory support (Commission E, ESCOP, EMA approved) and evidence for heart failure, whereas hibiscus is primarily studied for hypertension
• Compare with Olive Leaf for antihypertensive effects; both herbs have ACE-inhibitory mechanisms but lack head-to-head comparison studies
• Related to Garlic as another dietary/herbal intervention with evidence for blood pressure reduction; garlic has stronger overall evidence and regulatory approval
• The anthocyanin-mediated mechanisms in hibiscus share pharmacological similarities with Bilberry, though bilberry is studied primarily for vascular and ophthalmological applications